Biovica’s rights issue fully subscribed

Norwegian medtech company Medistim reported record third-quarter revenue of NOK 210.0 million, up 25.9% from NOK 166.8 million a year earlier. Operating profit rose 55.7% to NOK 63.1 million, and the board decided on the company’s first quarterly dividend, NOK 2.50 per share.

Oncopeptides has raised SEK 100 million before costs in a directed share issue to Swedish and international institutional investors. The money will fund the next clinical development phase of its glioblastoma program.

Dutch life science investor Forbion has raised EUR 2.3 billion (USD 2.6 billion) across two new funds. This is a record for the firm and one of the largest life science venture capital raises globally in the past five years. The new money comes into a European biotech market that has long been short of growth capital.

The company has closed a EUR 62.5 million Series B round, co-led by Novo Holdings and the Ljungström family office, to take its oral heart failure candidate AC01 through Phase 2b development and toward Phase 3 readiness by 2028.

The Helsinki-based company has closed a EUR 30 million Series A round led by Hadean Ventures to take its lead candidate, a TrkB potentiator designed to deliver the benefits of psychedelics without the hallucinations, into clinical trials for major depressive disorder.

The Oslo-based radiopharmaceutical company has raised NOK 148.5 million in a private placement and retail offering to complete its Phase 2 ovarian cancer trial and prepare for Phase 3.

Circio Holding has completed a private placement raising approximately NOK 200 million in gross proceeds, earmarked to accelerate a new in vivo CAR-T cell therapy programme built on the company's circVec circular-RNA platform.